16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies

16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies

Pediatric Intensive Care Unit (PICU) delirium and Iatrogenic Withdrawal Syndrome (IWS) are interrelated, highly prevalent complications of pediatric critical care pharmacotherapy. Historically overlooked or misattributed to "ICU psychosis" or normal pediatric distress, delirium is an acute organ dysfunction of the central nervous system characterized by fluctuating disturbances in attention, awareness, and cognition. Left unrecognized, pediatric delirium independently predicts prolonged mechanical ventilation, increased PICU length of stay, elevated healthcare expenditures, and post-intensive care syndrome in pediatrics (PICS-p), including long-term neurocognitive impairment and pediatric PTSD. Concurrently, prolonged sedation and analgesia invariably trigger neuroadaptation, physical dependence, and severe withdrawal upon discontinuation. This section reviews delirium phenotypes, validated screening instruments, modifiable risk factors, withdrawal scales, and pharmacokinetic weaning protocols.

---

Pediatric Delirium: Epidemiology and Subtypes

Delirium occurs in 20% to 30% of all general PICU admissions, surging to 50% to 65% in high-risk subsets, specifically infants under 2 years of age, mechanically ventilated children, and those following cardiopulmonary bypass surgery. Pediatric delirium is categorized into three clinical motoric subtypes:

Pediatric ICU Delirium Motoric Subtypes:

┌────────────────────┬──────────────┬────────────────────────────────────────────────────────┐
│ Delirium Subtype   │ Prevalence   │ Clinical Manifestation & Diagnostic Pitfalls           │
├────────────────────┼──────────────┼────────────────────────────────────────────────────────┤
│ Hypoactive         │ 60% to 70%   │ Apathy, lethargy, decreased responsiveness, blank stare│
│                    │ (MOST COMMON)│ Frequently missed; misdiagnosed as "good" or sedated   │
├────────────────────┼──────────────┼────────────────────────────────────────────────────────┤
│ Hyperactive        │ 10% to 15%   │ Combativeness, agitation, tachypnea, pulling lines/ET  │
│                    │              │ Readily identified; often treated inappropriately with │
│                    │              │ more benzodiazepines, worsening underlying delirium    │
├────────────────────┼──────────────┼────────────────────────────────────────────────────────┤
│ Mixed              │ 20% to 25%   │ Fluctuates between hyperactive restlessness and        │
│                    │              │ profound hypoactive lethargy across a 24-hour cycle   │
└────────────────────┴──────────────┴────────────────────────────────────────────────────────┘

Clinical Nuance of Hypoactive Delirium

Hypoactive delirium is the most prevalent subtype (60% to 70% of cases) but is profoundly underdiagnosed. Bedside clinicians frequently view the quiet, withdrawn child as "peaceful" or "appropriately rested." However, these children exhibit lack of eye contact, failure to recognize primary caregivers, delayed processing, and flattened affect. Hypoactive delirium carries the highest independent association with hospital mortality and sustained neurocognitive morbidity.

---

Validated Pediatric Delirium Screening Tools

Clinical guidelines from the Society of Critical Care Medicine (SCCM Pediatric PANDEM guidelines) mandate universal, routine screening for delirium at least once per 8- to 12-hour nursing shift.

Validation Spectrum for Pediatric Delirium Tools:

[Birth to 21 Years]  ──►  CAPD (Cornell Assessment of Pediatric Delirium)
                           - Validated across all ages, developmental delays, and intubated states
                           - 8-question observational instrument scored 0 to 4 (Total 0–32)
                           - Diagnostic Threshold: Score >= 9 indicates Delirium

[>= 5 Years]         ──►  pCAM-ICU (Pediatric Confusion Assessment Method for the ICU)
                           - 4-step algorithmic assessment of inattention and disorganized thinking

[6 Mo to 5 Years]    ──►  psCAM-ICU (Preschool CAM-ICU)
                           - Interactive non-verbal testing adapted for toddlers and preschoolers

1. Cornell Assessment of Pediatric Delirium (CAPD)

• Validated Population: Infants and children from birth through 21 years, including mechanically ventilated patients and those with pre-existing neurodevelopmental delays.
• Structure: An 8-item observational assessment completed at the end of an operational nursing shift:
  1. Does the child make eye contact with the caregiver?
  2. Are the child's actions purposeful?
  3. Is the child aware of their surroundings?
  4. Does the child express their needs/communicate?
  5. Is the child restless or agitated?
  6. Is the child inconsolable?
  7. Is the child underactive/slow to respond?
  8. Does it take the child a long time to respond to interactions?
• Scoring System: Items 1–4 are reverse-scored (4 = never, 0 = always); items 5–8 are standard-scored (0 = never, 4 = always). Total score ranges from 0 to 32.
• Diagnostic Cutoff: A score of >=9 indicates pediatric delirium (sensitivity 94%, specificity 79%).
• Developmental Anchor Points: The CAPD incorporates established developmental anchor questions for infants and children with developmental delays (e.g., assessing what behaviors are expected for a 6-month-old vs a 4-year-old), preventing false-positive scoring of baseline cognitive disabilities.

2. Pediatric CAM-ICU (pCAM-ICU) & Preschool CAM-ICU (psCAM-ICU)

• pCAM-ICU (Validated >=5 years): Assesses 4 algorithmic features: (1) Acute onset or fluctuating course of mental status, (2) Inattention (evaluated using a 10-letter visual or auditory vigilance task: letters "A-B-A-N-A-N-A-S"), (3) Altered level of consciousness (SBS score $\ne 0$ or RASS $\ne 0$), and (4) Disorganized thinking (answering simple binary questions). A patient must possess Features 1 and 2, PLUS either Feature 3 or 4.
• psCAM-ICU (Validated 6 months to 5 years): Employs non-verbal pictorial recognition tasks and simple behavioral observation adapted for pre-school cognitive levels.

---

Risk Factors & Non-Pharmacologic Management (The PANDEM Bundle)

Delirium results from a complex interplay between non-modifiable baseline vulnerabilities and modifiable acute critical illness exposures.

Modifiable vs Non-Modifiable Risk Factors for PICU Delirium:

NON-MODIFIABLE:
• Age < 2 Years (Immature synaptic plasticity & blood-brain barrier)
• Pre-existing Developmental Delay / Cognitive Impairment
• High Baseline Illness Severity (PIM3 / PRISM scores)
• Mechanical Ventilation / Cardiopulmonary Bypass / Cyanotic Heart Disease

MODIFIABLE (High-Impact Pharmacist Targets):
• BENZODIAZEPINE EXPOSURE (Continuous infusions confer 3x to 5x higher delirium odds)
• Anticholinergic Medication Burden (Atropine, Diphenhydramine, Ranitidine, Scopolamine)
• Deep Sedation / Immobility / Physical Restraints
• Environmental Dysregulation (Loss of day/night diurnal lighting, continuous alarms)
• Sleep Fragmentation & Disrupted Sleep Architecture

Benzodiazepines: The Strongest Modifiable Predictor

Multicenter pediatric trials demonstrate that continuous exposure to benzodiazepines (midazolam, lorazepam) is the single most powerful modifiable independent risk factor for delirium. Benzodiazepines alter normal neuro-architecture by causing excessive $GABA_A$ receptor activation, impairing cortical cholinergic transmission, disrupting normal sleep cycling (eliminating stage 3 slow-wave sleep and REM sleep), and inducing cognitive dissociation. Restricting benzodiazepine infusions through dexmedetomidine-based or opioid-sparing analgosedation protocols dramatically decreases PICU delirium rates.

Non-Pharmacologic Management (The Pediatric ABCDEF Bundle)

Non-pharmacologic bundle interventions represent the absolute first-line therapy for delirium prevention and treatment:

• A: Assess, Prevent, and Manage Pain (treat underlying nociceptive triggers first).
• B: Both Spontaneous Awakening Trials (SAT) and Spontaneous Breathing Trials (SBT).
• C: Choice of Analgesia and Sedation (minimize benzodiazepines; target light sedation).
• D: Delirium: Assess, Prevent, and Manage (routine CAPD screening).
• E: Early Mobility and Exercise (out of bed, physical therapy, passive range of motion).
• F: Family Engagement and Empowerment (familiar family presence, photos, personal clothing, re-orienting communication, diurnal day/night light cycles, clustering care to preserve uninterrupted nighttime sleep).

---

Pharmacologic Management of Refractory Agitated Delirium

Pharmacotherapy for pediatric delirium is strictly reserved for severe, refractory hyperactive delirium that poses imminent danger to patient safety (accidental extubation, central line dislodgement, severe combativeness) after all non-pharmacologic interventions have failed and underlying physiological causes ("I WATCH DEATH" mnemonic: Infection, Withdrawal, Acute metabolic, Trauma, CNS pathology, Hypoxia, Deficiencies, Endocrine, Acute vascular, Toxins, Heavy metals) have been ruled out.

Pharmacologic Treatment Algorithm for Refractory Hyperactive Delirium:

Step 1: Rule Out Reversible Causes: Hypoxemia, Shock, Hypoglycemia, Full Bladder, Pain, IWS
                                    │
                                    ▼
Step 2: Optimize Sleep Hygiene, Remove Physical Restraints, Involve Family at Bedside
                                    │
                                    ▼
Step 3: Discontinue Deliriogenic Offending Agents (Anticholinergics, Benzodiazepines)
                                    │
                                    ▼
Step 4: If Severe Agitation Threatens Airway/Access, Obtain Baseline 12-Lead ECG (QTc Interval)
                                    │
                                    ▼
Step 5: Initiate Low-Dose Atypical Antipsychotic (Quetiapine / Olanzapine) or Haloperidol
                                    │
                                    ▼
Step 6: Daily QTc Monitoring & Sedation Weaning; Discontinue Antipsychotic Within 3–7 Days

1. Atypical Antipsychotics (Second-Generation)

• Quetiapine (Seroquel): Preferred enteral agent for pediatric delirium.
  • Mechanism: Moderate dopamine $D_2$ antagonism combined with potent serotonin $5\text{-}HT_{2A}$ antagonism and histamine $H_1$ blockade (providing beneficial nocturnal sedation).
  • Dosing: 0.25 to 0.5 mg/kg/dose PO every 12 hours (starting dose 12.5 to 25 mg/dose in older children/adolescents; titrate gradually up to 1 to 2 mg/kg/day divided twice daily).
  • Virtues: Lowest propensity among antipsychotics for extrapyramidal symptoms (EPS) due to fast dissociation from $D_2$ receptors.
• Olanzapine (Zyprexa):
  • Dosing: 0.05 to 0.1 mg/kg/dose PO/IV once or twice daily (max initial 2.5 to 5 mg/dose).
  • Virtues: Available in orally disintegrating tablets (ODT) and parenteral formulations; useful when enteral access is unreliable.

2. Typical Antipsychotics (First-Generation): Haloperidol

• Haloperidol (Haldol):
  • Dosing: 0.025 to 0.05 mg/kg/dose IV/PO every 8 to 12 hours (max single dose: 1 to 2 mg in children, 5 mg in adolescents).
  • Mechanism: Potent, high-affinity $D_2$ receptor antagonist.
  • Adverse Effects: High risk of acute dystonic reactions, akathisia, and lowering of seizure threshold.

Mandatory Antipsychotic Safety Monitoring: QTc Prolongation

Antipsychotic agents block cardiac voltage-gated potassium channels ($I_{Kr}$, HERG gene), delaying ventricular repolarization and prolonging the electrocardiographic QTc interval, creating an absolute risk of fatal Torsades de Pointes and ventricular fibrillation.

• Baseline & Daily 12-Lead ECG: Mandatory prior to the first dose and daily during therapy.
• Safety Thresholds:
  • Baseline QTc must be <460 ms in males and <470 ms in females.
  • If during therapy the QTc exceeds 500 ms, or if the QTc increases by >60 ms from baseline, the antipsychotic must be immediately held or discontinued, and serum potassium (maintain $\ge 4.0 \text{ mEq/L}$) and serum magnesium (maintain $\ge 2.0 \text{ mg/dL}$) must be corrected.

---

Iatrogenic Withdrawal Syndrome (IWS)

Iatrogenic Withdrawal Syndrome occurs when high-dose continuous infusions of opioids and benzodiazepines administered for critical illness sedation are reduced or abruptly discontinued. Over 50% to 80% of children exposed to continuous opioid or benzodiazepine infusions for >5 to 7 days develop physical dependence.

Pathophysiologic Cascade of Iatrogenic Withdrawal:

Prolonged Infusion (>5-7 Days) ──► Receptor Downregulation & G-Protein Uncoupling
                                              │
                                              ▼
Abrupt Taper / Cessation        ──► Loss of Exogenous Inhibitory Tone
                                              │
                                              ▼
Massive Sympathetic Surge      ──► Locus Coeruleus Hyperarousal (Norepinephrine Surge)
                                              │
                                              ▼
Clinical Withdrawal Signs:      ──► CNS (Agitation, tremors, insomnia, seizures)
                                ──► Autonomic (Tachycardia, tachypnea, fever, diaphoresis)
                                ──► GI (Vomiting, loose stools, incoordinated suck)

Validated Withdrawal Assessment Instruments

1. Withdrawal Assessment Tool-1 (WAT-1):
   • Validated Population: Pediatric patients aged 0 to 18 years undergoing weaning from opioids or benzodiazepines.
   • Methodology: 11-item score incorporating a 2-minute pre-stimulus observation, a 1-minute stimulus observation, and a 2-minute post-stimulus observation (evaluating tremor, sweating, muscle tone, startle, and time to console).
   • Diagnostic Cutoff: A score of >=3 confirms Iatrogenic Withdrawal Syndrome and signals that the weaning schedule must be paused or slowed.
2. Sophia Observation withdrawal Scale (SOS): A 15-item observational scale validated in PICU populations to assess opioid and benzodiazepine withdrawal.

---

Pharmacokinetic Weaning Protocols & Dose Titration

Preventing or managing IWS requires converting short-acting continuous infusions into long-acting enteral formulations, followed by a gradual, calculated taper.

Opioid Weaning Protocol: Continuous IV Fentanyl to Enteral Methadone:

Step 1: Calculate Total 24-Hour IV Fentanyl Consumption (mcg/day)
                                     │
                                     ▼
Step 2: Convert IV Fentanyl to IV Morphine Milligram Equivalents (MME)
        (Formula: 100 mcg IV Fentanyl = 10 mg IV Morphine; divide mcg fentanyl by 10)
                                     │
                                     ▼
Step 3: Convert IV Morphine to Daily Oral Methadone Base (1 : 1 Ratio)
        (Total Daily PO Methadone in mg = Total Daily IV Morphine in mg)
                                     │
                                     ▼
Step 4: Divide Daily Methadone into 2 to 4 Divided Doses (Every 6 to 12 Hours)
        (Standard Pediatric Starting Dose: 0.1 mg/kg/dose PO q6h to q12h)
                                     │
                                     ▼
Step 5: Overlap PO Methadone with IV Fentanyl for 24–48 Hours While Methadone Reaches Steady State
                                     │
                                     ▼
Step 6: Discontinue IV Infusion and Wean Methadone by 10% to 20% Every 24 to 48 Hours

1. Methadone Conversion for Opioid Physical Dependence

Methadone is a synthetic opioid agonist with unique pharmacological properties: high oral bioavailability (70% to 80%), non-competitive NMDA receptor antagonism (which prevents and reverses opioid tolerance and hyperalgesia), and an extended, variable elimination half-life (15 to 60+ hours in pediatrics due to complex CYP3A4, CYP2B6, and CYP2C19 metabolism).

• Conversion Calculation:
  • Calculate cumulative 24-hour IV fentanyl intake (mcg).
  • Convert to IV Morphine Equivalents: $\text{IV Morphine (mg)} = \frac{\text{IV Fentanyl (mcg)}}{10}$.
  • Convert to Oral Methadone: In pediatric critical care weaning protocols, total daily oral methadone is typically initiated at a 1 : 1 ratio to total daily IV morphine equivalents (or 100% to 120% of IV morphine equivalents).
  • Divide into equal doses administered every 6 to 12 hours (typically every 8 or 12 hours; initial single dose capped at 0.1 to 0.2 mg/kg/dose).
• Titration Dynamics: Due to its long elimination half-life, methadone requires 48 to 72 hours to achieve steady-state plasma concentrations. Dose changes must not be made more frequently than every 48 hours to avoid unexpected drug accumulation and delayed respiratory depression.

2. Weaning Rate Schedules

• Short Exposure (Infusions for 5 to 10 days): Fast taper: Decrease dose by 15% to 20% every 24 to 48 hours over 5 to 10 days.
• Prolonged Exposure (Infusions for >10 to 14 days): Slow taper: Decrease dose by 10% to 15% every 48 to 72 hours over 2 to 4 weeks. If the patient develops a WAT-1 score $\ge 3$, return to the previous effective dose for 24 hours, then resume weaning at half the previous decrement rate.

3. Benzodiazepine Weaning

Convert continuous IV midazolam to long-acting enteral lorazepam (0.05 to 0.1 mg/kg/dose PO every 6 to 8 hours) or clonazepam (0.01 to 0.03 mg/kg/dose PO every 8 to 12 hours). Taper by 10% to 20% every 48 hours.

4. Alpha-2 Adrenergic Agonists: Clonidine & Dexmedetomidine

Sympathetic hyperactivity (sweating, tachycardia, hypertension, restlessness) is the hallmark of withdrawal, driven by hyperactive locus coeruleus noradrenergic discharge.

• Clonidine (Enteral / Transdermal): Acts on presynaptic central alpha-2 receptors to suppress norepinephrine release.
  • Dosing: 1 to 5 mcg/kg/dose PO every 6 to 8 hours (start low at 1–2 mcg/kg/dose and titrate based on blood pressure and heart rate).
  • Facilitates faster opioid and benzodiazepine tapers and reduces WAT-1 scores.
  • Transdermal Clonidine: Can be initiated for outpatient weaning (releases 0.1, 0.2, or 0.3 mg/day over 7 days); requires 48 hours to achieve therapeutic plasma levels; oral overlap is necessary.
• Dexmedetomidine Weaning Bridge: Transitioning from continuous IV dexmedetomidine to oral clonidine uses an approximate conversion: $1 \text{ mcg/kg/hour of IV dexmedetomidine} \approx 1 \text{ to } 2 \text{ mcg/kg PO every 6 hours of clonidine}$.

---

Practice Pearls & BCPPS Exam Traps

• Exam Trap 1 (Missed Hypoactive Delirium): When evaluating a quiet, staring, mechanically ventilated toddler with a CAPD score $\ge 9$, do not prescribe more sedation (e.g., midazolam boluses). Benzodiazepines are the primary driver of delirium; the correct intervention is initiating the non-pharmacologic bundle and weaning benzodiazepines.
• Exam Trap 2 (CAPD vs WAT-1 Scoring): Do not confuse delirium assessment with withdrawal assessment. Delirium is evaluated with the CAPD (threshold $\ge 9$); withdrawal is evaluated with the WAT-1 (threshold $\ge 3$). If a patient has a WAT-1 of 5 and autonomic signs, treat withdrawal by pausing the wean or adding clonidine, not by prescribing an antipsychotic.
• Exam Trap 3 (Antipsychotic QTc Rule): Prior to initiating quetiapine, olanzapine, or haloperidol for refractory agitated delirium, always obtain a 12-lead baseline ECG. If QTc is $>500 \text{ ms}$ or prolongs by $>60 \text{ ms}$, hold the drug and correct hypokalemia and hypomagnesemia.
• Exam Trap 4 (Methadone Accumulation): Never escalate a methadone dose within 24 hours of initiation. Because methadone's elimination half-life spans 15 to 60 hours, steady-state is not reached for 3 to 5 days; early aggressive escalation leads to delayed, fatal respiratory depression.